With COVID-19 cases surging in many parts of the world, the need is high for multiple vaccines to slow the virus.
But the fate of adenovirus-vectored vaccines from AstraZeneca and Johnson & Johnson has become murky after a limited number of people receiving those vaccines have developed severe blood clot disorders.
Officials in both the EU and the U.S. suspect there could be a link between adenovirus-based COVID-1 vaccines and blood clotting problems such as cerebral venous sinus thrombosis. Authorities in both countries have either temporarily halted or constrained the use of adenovirus vaccines. FDA anticipates that the pause in J&J vaccine use will last a matter of days.
Get the full story from our sister site, Drug Discovery & Development.